Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

<p>Abstract</p> <p>Background</p> <p>As a member of the TNF superfamily, TRAIL could induce human tumor cell apoptosis through its cognate death receptors DR4 or DR5, which can induce formation of the death inducing signaling complex (DISC) and activation of the membran...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Qiao Chunxia, Hu Meiyun, Guo Leiming, Lv Ming, Lin Zhou, Geng Jing, Lang Xiaoling, Li Xinying, Li Yan, Ma Yuanfang, Feng Jiannan, Shen Beifen
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: BMC 2012-07-01
Cyfres:BMC Immunology
Pynciau:
TRAIL
Death receptor 5
Monoclonal antibody
Apoptosis
Breast cancer
Mynediad Ar-lein:http://www.biomedcentral.com/1471-2172/13/40

Rhyngrwyd

http://www.biomedcentral.com/1471-2172/13/40

Eitemau Tebyg